{
    "nct_id": "NCT04713982",
    "official_title": "Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease",
    "inclusion_criteria": "* Diagnosis of HD with documented CAG repeat ≥ 37\n* UHDRS total maximal chorea score of ≥ 8\n* Able to walk at least 10 meters\n* Medically stable outpatient, based on the investigator's judgment\n* Willing and able to give written informed consent prior to performing any study procedures\n* Have completed at least 10th grade\n* Montreal Cognitive Assessment score ≥ 22 on screening\n* Female subjects of childbearing potential agree to use an acceptable method of contraception from screening through study completion\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Severe depression or suicidal ideation\n* History of suicidal behavior\n* Unstable or serious medical or psychiatric illness\n* Renal or hepatic impairment\n* Severe speech impairment or anarthria\n* Inability to swallow study medication\n* Women who are pregnant or breast feeding\n* History of alcohol or substance abuse within the last 12 months\n* Current use of VMAT2 inhibitor (tetrabenazine, deutetrabenazine, valbenazine)\n* Concurrent participation in any other investigational drug trials\n* EKG QTcF> 500 mse",
    "miscellaneous_criteria": ""
}